Could a magnetic field tame autoimmune disease? new trial begins
NCT ID NCT07221565
First seen Nov 01, 2025
Summary
This study tests a non-invasive device that uses low-frequency electromagnetic waves to help immune cells communicate better. The goal is to reduce flare-ups in people with lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive 20-minute sessions three times a week for 12 weeks, with half getting a placebo device. The trial will also analyze blood samples to understand how the treatment affects immune signals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)
New York, New York, 10016, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR) device
What this could lead to
If successful, this could offer a non-invasive, drug-free way to reduce autoimmune flare-ups and symptoms for conditions like lupus, rheumatoid arthritis, and multiple sclerosis.
What could go wrong
This is an early Phase I/II trial with only 120 participants, so results may not apply to everyone. The device is experimental, and its effects on immune regulation are still unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.